Genetic Polymorphisms of miR-146a and miR-155 in Psoriasis and Psoriatic Arthritis: Evidence from a Turkish Case-Control Study
Keywords:
Psoriasis, Psoriatic arthritis,MiR-146a, MiR-155, Genetic polymorphismAbstract
Introduction: Psoriasis, a widespread inflammatory cutaneous disease, is driven by an interplay of genetic and environmental risk factors. miR-155 and miR-146a have been implicated in the regulation of inflammatory pathways.
Objectives: In the current study, we examined the association between miR-155 rs767649 and miR-146a rs2910164 variants and the predisposition to psoriasis and psoriatic arthritis.
Methods: A total of 544 individuals, including 284 psoriasis cases (68 with psoriatic arthritis) and 260 controls, were enrolled in the present study. Real-time polymerase chain reaction (qPCR) method was used to detect the genotypes of study groups.
Results: The frequencies of the rs2910164 C allele, CC, and GC genotypes were significantly higher in the patient group (P<0.001), while the frequencies of the rs767649 A allele and AA genotype were higher in the control group (P=0.005 and P=0.002, respectively). No statistically significant difference in genotype or allele frequency was observed between patients with and without psoriatic arthritis (P>0.05). Rs2910164 CC and GC genotypes were found to be associated with a younger age at disease onset (P=0.006), and CC genotype was associated with higher PASI score (P=0.024).
Conclusion: The present data suggest an association between the presence of the miR-155 rs767649 and miR-146a rs2910164 variants and susceptibility to psoriasis in the Turkish population. However, although the number of patients with psoriatic arthritis in our study was relatively small, no association was found between these variants and the development of psoriatic arthritis. Furthermore, the rs2910164 polymorphism was found to be associated with both early-onset disease and PASI score.
References
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet (London, England). 2021;397(10281):1301-1315. DOI:10.1016/S0140-6736(20)32549-6 PMID: 33812489.
Yang SF, Lin MH, Chou PC, et al. Genetics of Generalized Pustular Psoriasis: Current Understanding and Implications for Future Therapeutics. Genes (Basel). 2023;14(6):1297. DOI:10.3390/GENES14061297 PMID: 37372477.
Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437. DOI:10.1038/S41392-023-01655-6 PMID: 38008779
Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Northfield Il). 2021;21(3):170. DOI:10.7861/CLINMED.2021-0257 PMID: 34001566
Mateu-Arrom L, Puig L. Genetic and Epigenetic Mechanisms of Psoriasis. Genes (Basel). 2023;14(8):1619. DOI:10.3390/GENES14081619 PMID: 37628670
Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022;13:880201. DOI:10.3389/FIMMU.2022.880201 PMID: 35757712
Yamazaki F. Psoriasis: Comorbidities. J Dermatol. 2021;48(6):732-740. DOI:10.1111/1346-8138.15840 PMID: 33763899
Kiełbowski K, Bakinowska E, Ostrowski P, et al. The Role of Adipokines in the Pathogenesis of Psoriasis. Int J Mol Sci. 2023;24(7):6390. DOI:10.3390/IJMS24076390 PMID: 37047363
Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. Acta Derm Venereol. 2020;100(3):54-64. DOI:10.2340/00015555-3384 PMID: 31971603
Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020;99(1):2-8. DOI:10.1016/J.JDERMSCI.2020.05.008 PMID: 32536600
Jiang X, Shi R, Ma R, et al. The role of microRNA in psoriasis: A review. Exp Dermatol. 2023;32(10):1598-1612. DOI:10.1111/exd.14871 PMID: 37382420
Shao LN, Wang N, Zhou SH, Wang Z. Associations between human leukocyte antigen C locus polymorphism and psoriatic arthritis in populations of European and Middle Eastern descent: a meta-analysis. Ann Saudi Med. 2020;40(4):338. DOI:10.5144/0256-4947.2020.338 PMID: 32757989
Caputo V, Strafella C, Termine A, et al. RNAseq-Based Prioritization Revealed COL6A5, COL8A1, COL10A1 and MIR146A as Common and Differential Susceptibility Biomarkers for Psoriasis and Psoriatic Arthritis: Confirmation from Genotyping Analysis of 1417 Italian Subjects. Int J Mol Sci. 2020;21(8):2740. DOI:10.3390/IJMS21082740 PMID: 32326527
Ghosh D, Ganguly T, Chatterjee R. Emerging roles of non-coding RNAs in psoriasis pathogenesis. Funct Integr Genomics. 2023;23(2). DOI:10.1007/S10142-023-01057-5 PMID: 37072609
Maharaj AB, Naidoo P, Ghazi T, et al. MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis. BMC Med Genet. 2018;19(1):48. DOI:10.1186/S12881-018-0565-1 PMID: 29587639
Zhang W, Yi X, Guo S, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med. 2014;18(11):2225-2234. DOI:10.1111/JCMM.12359 PMID: 25209759
Park R, Lee WJ, Ji JD. Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis. Autoimmunity. 2016;49(7):451-458. DOI:10.3109/08916934.2016.1171854 PMID: 27098222.
Nani P, Ladopoulou M, Papaioannou EH, et al. Pharmacogenetic Analysis of the MIR146A rs2910164 and MIR155 rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn’s Disease and Psoriasis. Genes (Basel). 2023;14(2):445. DOI:10.3390/GENES14020445/S1 PMID: 36833372
Chatzikyriakidou A, Voulgari P V., Georgiou I, Drosos AA. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010;71(5):382-385. DOI:10.1111/J.1365-3083.2010.02381.X PMID: 20500689.
Hao X, Xia L, Qu R, Yang X, Jiang M, Zhou B. Association between miR-146a rs2910164 polymorphism and specific cancer susceptibility: an updated meta-analysis. Fam Cancer. 2018;17(3):459-468. DOI:10.1007/S10689-017-0056-0 PMID: 29127520.
Wang D, Wang Y, Lin Z, Cai L. Association between miRNA-146a polymorphism and lung cancer susceptibility: A meta-analysis involving 6506 cases and 6576 controls. Gene. 2020;757:144940. DOI:10.1016/J.GENE.2020.144940 PMID: 32640303.
Wang BR, Chang WS, Liao CH, et al. Impacts of Mir146a Genotypes on Bladder Cancer Risk in Taiwan. Biomedicines. 2023;11(5):1396. DOI:10.3390/BIOMEDICINES11051396 PMID: 37239070.
Gong HB, Zhang SL, Wu XJ, Pu XM, Kang XJ, Marzano AV. Association of rs2910164 polymorphism in MiR-146a gene with psoriasis susceptibility: A meta-analysis. Medicine (Baltimore). 2019;98(6):e14401. DOI:10.1097/MD.0000000000014401 PMID: 30732186.
Ghafouri-Fard S, Eghtedarian R, Taheri M, Rakhshan A. The eminent roles of ncRNAs in the pathogenesis of psoriasis. Non-coding RNA Res. 2020;5(3):99-108. DOI:10.1016/J.NCRNA.2020.06.002 PMID: 32695942.
Soonthornchai W, Tangtanatakul P, Meephansan J, et al. Down-regulation of miR-155 after treatment with narrow-band UVB and methotrexate associates with apoptosis of keratinocytes in psoriasis. Asian Pacific J allergy Immunol. 2021;39(3):206-213. DOI:10.12932/AP-031218-0451 PMID: 30904000.
Guo W, Xu F, Zhuang Z, Liu Z, Xie J, Bai L. Ebosin Ameliorates Psoriasis-Like Inflammation of Mice via miR-155 Targeting tnfaip3 on IL-17 Pathway. Front Immunol. 2021;12:662362. DOI:10.3389/FIMMU.2021.662362/FULL PMID: 33981308.
Iranparast S, Tahmasebi-Birgani M, Motamedfar A, Amari A, Ghafourian M. miR-155 rs767649 T>A gene polymorphism is associated with downregulation of miR-155 expression, suppressor of cytokine signaling-1 overexpression, and low probability of metastatic tumor at the time of breast cancer diagnosis. J Res Med Sci. 2023;28(1):32. DOI:10.4103/JRMS.JRMS_960_21 PMID: 37213455.
Beer L, Kalinina P, Köcher M, et al. miR-155 Contributes to Normal Keratinocyte Differentiation and Is Upregulated in the Epidermis of Psoriatic Skin Lesions. Int J Mol Sci. 2020;21(23):1-16. DOI:10.3390/IJMS21239288 PMID: 33291448.
Gu D, Cheng M, Feng J. Expression of miR-155 and miR-146a in Skin Tissue, Peripheral Blood Mononuclear Cells and Serum of Patients with Psoriasis and Its Clinical Significance. Adv Biosci Biotechnol. 2022;13:207-215. DOI:10.4236/abb.2022.134011
Leal B, Carvalho C, Ferreira AM, et al. Serum Levels of miR-146a in Patients with Psoriasis. Mol Diagn Ther. 2021;25(4):475-485. DOI:10.1007/S40291-021-00531-9 PMID: 33937970.
Avgeros C, Patsatsi A, Dimitriadis D, et al. Dysregulation of Plasma miR-146a and miR-155 Expression Profile in Mycosis Fungoides Is Associated with rs2910164 and rs767649 Polymorphisms. Int J Mol Sci. 2022;24(1):271. DOI:10.3390/IJMS24010271 PMID: 36613718.
Srivastava A, Nikamo P, Lohcharoenkal W, et al. MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis. J Allergy Clin Immunol. 2017;139(2):550-561. DOI:10.1016/J.JACI.2016.07.025 PMID: 27568078.
NCBI Reference SNP (rs) Report. Accesed: March 28, 2025. https://www.ncbi.nlm.nih.gov/snp/rs2910164
Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, De La Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269-7274. DOI:10.1073/pnas.0802682105 PMID: 18474871.
Yin Z, Cui Z, Ren Y, Xia L, Li H, Zhou B. MiR-146a polymorphism correlates with lung cancer risk in Chinese nonsmoking females. Oncotarget. 2016;8(2):2275. DOI:10.18632/ONCOTARGET.13722 PMID: 27911870.
Mohammed SR, Shaker OG, Mohammed AA, et al. Impact of miR-155 (rs767649 A>T) and miR-146a (rs57095329 A>G) polymorphisms in System Lupus Erythematosus susceptibility in an Egyptian cohort. Eur Rev Med Pharmacol Sci. 2021;25(3):1425-1435. DOI:10.26355/EURREV_202102_24850 PMID: 33629312.
Wang R, Wei A, Zhang Y, et al. Association between genetic variants of microRNA-21 and microRNA-155 and systemic lupus erythematosus: A case-control study from a Chinese population. J Clin Lab Anal. 2022;36(7). DOI:10.1002/JCLA.24518 PMID: 35707883.
Ali MA, Shaker OG, Eid HM, Mahmoud EE, Ezzat EM, Gaber SN. Relationship between miR-155 and miR-146a polymorphisms and susceptibility to multiple sclerosis in an Egyptian cohort. Biomed reports. 2020;12(5):276-284. DOI:10.3892/BR.2020.1286 PMID: 32257191.
Shaker OG, Abdelaleem OO, Fouad NA, et al. MiR-146a and miR-155 polymorphisms in Egyptian patients with Behcet’s disease. Arch Med Sci. 2021;18(6):1467-1474. DOI:10.5114/AOMS/105349 PMID: 36457982.
Elghouneimy MA, Ramadan MA, Farrag EA, et al. Impact of miR-155 rs767649 Polymorphism on Rheumatoid Arthritis Activity in Egyptian Patients. Cureus. 2023;15(11):e49297. DOI:10.7759/CUREUS.49297 PMID: 38351964.
Shaker OG, Abdelaleem OO, Fouad NA, et al. Association Between miR-155, Its Polymorphism and Ischemia-Modified Albumin in Patients with Rheumatoid Arthritis. J Interferon Cytokine Res. 2019;39(7):428-437. DOI:10.1089/JIR.2019.0001 PMID: 31009294.
Xie K, Ma H, Liang C, et al. A functional variant in miR-155 regulation region contributes to lung cancer risk and survival. Oncotarget. 2015;6(40):42781-42792. DOI:10.18632/ONCOTARGET.5840 PMID: 26543233.
Dezfuli NK, Adcock IM, Alipoor SD, et al. The miR-146a SNP Rs2910164 and miR-155 SNP rs767649 Are Risk Factors for Non-Small Cell Lung Cancer in the Iranian Population. Can Respir J. 2020;2020:8179415. DOI:10.1155/2020/8179415 PMID: 33294082.
Ji J, Xu M, Tu J, et al. MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of hepatocellular carcinoma. Oncotarget. 2016;7(37):60303-60309. DOI:10.18632/ONCOTARGET.11206 PMID: 27531892.
Wang S, Cao X, Ding B, et al. The rs767649 polymorphism in the promoter of miR-155 contributes to the decreased risk for cervical cancer in a Chinese population. Gene. 2016;595(1):109-114. DOI:10.1016/J.GENE.2016.10.002 PMID: 27717891.
Budu-Aggrey A, Bowes J, Loehr S, et al. Replication of a distinct psoriatic arthritis risk variant at the IL23R locus. Ann Rheum Dis. 2016;75(7):1417-1418. DOI:10.1136/ANNRHEUMDIS-2016-209290 PMID: 27016051.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Fadime Mutlu İçduygu, Isil Deniz Oguz, Egemen Akgun, Burak Aksan, Sevgi Kulakli, Ebru Alp
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
